We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

WYETH-AYERST TO PAY AFFYMAX $57 MIL. IN DRUG DISCOVERY AGREEMENT

News

Executive Summary

WYETH-AYERST TO PAY AFFYMAX $57 MIL. IN DRUG DISCOVERY AGREEMENT in exchange for worldwide rights to any potential products developed under the five-year collaboration. Announced Feb. 28, the agreement calls for Wyeth-Ayerst to make $47 mil. in R&D payments to Affymax over five years to fund a drug discovery program at Affymax' Palo Alto, Calif. facility. Wyeth will also purchase $10 mil. of Affymax common stock at $20 per share, or approximately 500,000 shares, giving the company about a 3% equity stake. Affymax will have 15.9 mil. shares outstanding post- transaction.